Cargando…

Application of the 21-Gene Recurrence Score in Patients with Early HR-Positive/HER2-Negative Breast Cancer: Chemotherapy and Survival Rate According to Clinical Risk

SIMPLE SUMMARY: It is important to address the influence of 21-gene Recurrence Score (RS) on chemotherapy decision-making stratified by clinical risk in patients with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. Our study presented that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bae, Soong June, Ahn, Sung Gwe, Ji, Jung Hwan, Chu, Chihhao, Kim, Dooreh, Lee, Janghee, Cha, Yoon Jin, Jeong, Joon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394098/ https://www.ncbi.nlm.nih.gov/pubmed/34439158 http://dx.doi.org/10.3390/cancers13164003

Ejemplares similares

YAP1 Expression in HR+HER2− Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation
por: Park, Inho, et al.
Publicado: (2023)

Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

Author Correction: Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

Association between TP53 mutation and high 21-gene recurrence score in estrogen receptor-positive/HER2-negative breast cancer
por: Ji, Jung Hwan, et al.
Publicado: (2022)

Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Early Standardized Uptake Value Reduction in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy
por: Bae, Soong June, et al.
Publicado: (2022)

Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node‐positive, HER2‐positive breast cancer
por: Cha, Chihwan, et al.
Publicado: (2021)

Comparison of complications according to incision types in nipple-sparing mastectomy and immediate reconstruction
por: Park, Soeun, et al.
Publicado: (2020)

Relationship of the standard uptake value of (18)F-FDG-PET-CT with tumor-infiltrating lymphocytes in breast tumors measuring ≥ 1 cm
por: Park, Soeun, et al.
Publicado: (2021)

Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay
por: Ahn, Sung Gwe, et al.
Publicado: (2017)

Association of Body Mass Index With 21-Gene Recurrence Score Among Women With Estrogen Receptor–Positive, ERBB2–Negative Breast Cancer
por: Lee, Janghee, et al.
Publicado: (2022)

Body mass index and absolute lymphocyte count predict disease-free survival in Korean breast cancer patients
por: Ko, Sung Min, et al.
Publicado: (2021)

Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2018)

Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index
por: Lee, Janghee, et al.
Publicado: (2020)

Author Correction: Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index
por: Lee, Janghee, et al.
Publicado: (2021)

Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy
por: Bae, Soong June, et al.
Publicado: (2020)

The Impact of Post-Mastectomy Radiotherapy on Survival Outcomes in Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy
por: Lee, Janghee, et al.
Publicado: (2021)

Ki-67, 21-Gene Recurrence Score, Endocrine Resistance, and Survival in Patients With Breast Cancer
por: Lee, Janghee, et al.
Publicado: (2023)

Repeat Sentinel Lymph Node Biopsy for Ipsilateral Breast Tumor Recurrence After Breast Conserving Surgery With Sentinel Lymph Node Biopsy: Pooled Analysis Using Data From a Systematic Review and Two Institutions
por: Yoon, Chang Ik, et al.
Publicado: (2020)

Residual Tumor Patterns of Breast Cancer on MRI after Neo-Adjuvant Chemotherapy: Impact on Clinicopathologic Factors and Prognosis
por: Cha, Yoon Jin, et al.
Publicado: (2022)

Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP
por: Ji, Jung Hwan, et al.
Publicado: (2022)

Prognostic impact of radiotherapy-induced-lymphopenia in patients treated with breast-conservative surgery
por: Yoon, Chang Ik, et al.
Publicado: (2023)

Does the 21-gene recurrence score have clinical utility in HR+/HER2+ breast cancer?
por: Bilani, Nadeem, et al.
Publicado: (2022)

(18)F-FDG uptake of visceral adipose tissue on preoperative PET/CT as a predictive marker for breast cancer recurrence
por: Kim, Hyun Jeong, et al.
Publicado: (2022)

High Nuclear Expression of Yes-Associated Protein 1 Correlates With Metastasis in Patients With Breast Cancer
por: Cha, Yoon Jin, et al.
Publicado: (2021)

PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection
por: Cha, Yoon Jin, et al.
Publicado: (2021)

Low PR in ER(+)/HER2(−) breast cancer: high rates of TP53 mutation and high SUV
por: Ahn, Sung Gwe, et al.
Publicado: (2018)

Radiotherapy-Induced High Neutrophil-to-Lymphocyte Ratio is a Negative Prognostic Factor in Patients with Breast Cancer
por: Yoon, Chang Ik, et al.
Publicado: (2020)

The association between the expression of nuclear Yes-associated protein 1 (YAP1) and p53 protein expression profile in breast cancer patients
por: Cha, Yoon Jin, et al.
Publicado: (2021)

Metastasis Risk Assessment Using BAG2 Expression by Cancer-Associated Fibroblast and Tumor Cells in Patients with Breast Cancer
por: Yoon, Chang-Ik, et al.
Publicado: (2021)

Correlation of Yes-Associated Protein 1 with Stroma Type and Tumor Stiffness in Hormone-Receptor Positive Breast Cancer
por: Lee, Yangkyu, et al.
Publicado: (2022)

Optimal treatment strategy for hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer patients with 1–2 suspicious axillary lymph node metastases on breast magnetic resonance imaging: upfront surgery vs. neoadjuvant chemotherapy
por: Lee, Seung Eun, et al.
Publicado: (2023)

SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer
por: Baek, Seung Ho, et al.
Publicado: (2022)

Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer
por: Bae, Soong June, et al.
Publicado: (2021)

Comparison of patients with small (≤2 cm) breast cancer according to adherence to breast screening program
por: Park, Jung Min, et al.
Publicado: (2017)

Investigation of Factors Affecting Adherence to Adjuvant Hormone Therapy in Early-Stage Breast Cancer Patients: A Comprehensive Systematic Review
por: Yang, Seongwoo, et al.
Publicado: (2023)

Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2017)

Associations between absolute neutrophil count and lymphocyte-predominant breast cancer
por: Yoon, Chang Ik, et al.
Publicado: (2019)

Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2021)

Controversies and Opportunities in the Clinical Daily Use of the 21-Gene Assay for Prognostication and Prediction of Chemotherapy Benefit in HR+/HER2- Early Breast Cancer
por: Jacobs, Flavia, et al.
Publicado: (2022)

The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR(+)HER2(−) metastatic breast cancer: a retrospective study
por: Shao, Bin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1mtc1k5j14e2nkvj9cv3hib6a3